Implication of Perivascular Adipose Tissue as a Potential Therapeutic Target for the Vascular Defensive Actions of Incretin-Based Therapies and SGLT2 Inhibitors
Cardiovascular Toxicology · 2026-12 · 26 (12)
DOI: 10.1007/s12012-026-10218-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Toxicology, online erschienen am 13.11.2026. Verfasst von Pitchai Balakumar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Office of Research and Development, Periyar Maniammai Institute of Science & Technology (Deemed to be University), Thanjavur, Tamil Nadu, 613 403, In…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Incretins, Adipose Tissue, Cardiovascular Diseases. Die Arbeit nennt 64 Literaturangaben. Gefördert von: Deanship of Research and Graduate Studies at King Khalid University.
Abstract (Originalsprache)
Cardiovascular disease is a predominant cause of illness in individuals with type 2 diabetes mellitus and obesity. Although glucose reduction has traditionally been the principal therapeutic target for treating hyperglycemia, recent cardiovascular outcome trials have revealed that incretin-based therapies and sodium-glucose cotransporter-2 (SGLT2) inhibitors provide significant cardiovascular benefits beyond merely lowering blood glucose levels. The precise mechanisms underlying the multifaceted vascular effects of these therapies are not fully understood. Perivascular adipose tissue (PVAT) has been identified as an active player in regulating vascular tone and inflammation. Under physiological conditions, PVAT exhibits anticontractile and vasoprotective effects; however, under metabolic and cardiovascular pathological conditions, PVAT undergoes inflammatory and oxidative remodeling, which can lead to endothelial dysfunction, increased arterial stiffness, and hypertension. Recent experimental and translational studies suggest that incretin-based therapies and SGLT2 inhibitors may help improve the homeostasis of PVAT, consequently enhancing vascular function and regulating blood pressure. Despite these developments, the potential role of PVAT as a target for metabolic therapies has not been thoroughly reviewed. This review aims to address this critical knowledge gap and proposes PVAT and its signaling as novel therapeutic targets through which incretin-based treatments and SGLT2 inhibitors could provide vascular protection, thereby redefining cardiometabolic pharmacotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Office of Research and Development, Periyar Maniammai Institute of Science & Technology (Deemed to be University), Thanjavur, Tamil Nadu, 613 403, India. pbalakumar2022@gmail.com.
- School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Selangor, Malaysia. pbalakumar2022@gmail.com.
- Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Al-Qara, 61421, Abha, Saudi Arabia.
Förderung
- Deanship of Research and Graduate Studies at King Khalid University
Zitieren
APA
Balakumar, P., Khan, N. A., Easwaran, V., & Orayj, K. M. (2026). Implication of Perivascular Adipose Tissue as a Potential Therapeutic Target for the Vascular Defensive Actions of Incretin-Based Therapies and SGLT2 Inhibitors. Cardiovascular Toxicology, 26(12). https://doi.org/10.1007/s12012-026-10218-4
Vancouver
Balakumar P, Khan NA, Easwaran V, Orayj KM. Implication of Perivascular Adipose Tissue as a Potential Therapeutic Target for the Vascular Defensive Actions of Incretin-Based Therapies and SGLT2 Inhibitors. Cardiovascular Toxicology. 2026;26(12). doi:10.1007/s12012-026-10218-4
BibTeX
@article{Balakumar2026,
author = {Balakumar, Pitchai and Khan, Noohu Abdulla and Easwaran, Vigneshwaran and Orayj, Khalid M},
title = {Implication of Perivascular Adipose Tissue as a Potential Therapeutic Target for the Vascular Defensive Actions of Incretin-Based Therapies and SGLT2 Inhibitors},
journal = {Cardiovascular Toxicology},
year = {2026},
volume = {26},
number = {12},
doi = {10.1007/s12012-026-10218-4}
}
EUVIMED